A world-first Australian trial has found that a simple fingerstick test for hepatitis B DNA is as accurate as standard lab testing, paving the way for wider access in remote and resource-limited settings. 

Published in the Journal of Clinical Microbiology, the study showed that the point-of-care test can deliver results within an hour and be performed in decentralised clinics, Xinhua news agency reported.